Floatz logo

Candesartan Cilexetil

Resistant Hypertension

PD Dr. Grégoire WuerznerSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Resistant Hypertension cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Candesartan Cilexetil is also rated in:

hypertensive disorderDormant
BB
Indicative ·
65 / 100
View asset →
obesity disorderDormant
B
Indicative ·
56 / 100
View asset →
stroke disorderDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →